NZ623123A - A process for concentration of a polypeptide - Google Patents

A process for concentration of a polypeptide

Info

Publication number
NZ623123A
NZ623123A NZ62312307A NZ62312307A NZ623123A NZ 623123 A NZ623123 A NZ 623123A NZ 62312307 A NZ62312307 A NZ 62312307A NZ 62312307 A NZ62312307 A NZ 62312307A NZ 623123 A NZ623123 A NZ 623123A
Authority
NZ
New Zealand
Prior art keywords
functionally equivalent
polypeptide
equivalent parts
analogues hereof
galactocerebrosidase
Prior art date
Application number
NZ62312307A
Other languages
English (en)
Inventor
Stefan Nilsson
Original Assignee
Zymenex As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymenex As filed Critical Zymenex As
Publication of NZ623123A publication Critical patent/NZ623123A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01061—Hydroxymethylbilane synthase (2.5.1.61)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01024—Alpha-mannosidase (3.2.1.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01046—Galactosylceramidase (3.2.1.46)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Water Supply & Treatment (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NZ62312307A 2006-04-04 2007-04-04 A process for concentration of a polypeptide NZ623123A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200600488 2006-04-04
DKPA200600922 2006-07-05
NZ607595A NZ607595A (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide

Publications (1)

Publication Number Publication Date
NZ623123A true NZ623123A (en) 2015-04-24

Family

ID=38472949

Family Applications (7)

Application Number Title Priority Date Filing Date
NZ62312307A NZ623123A (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide
NZ607595A NZ607595A (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide
NZ588903A NZ588903A (en) 2006-04-04 2007-04-04 A process for concentration of galactosycerebrosidase or porphobuilinogen deaminase
NZ582045A NZ582045A (en) 2006-04-04 2007-04-04 A pharmaceutical composition comprising at least 10mg/mL of alfa mannosidase and less that 5% total protein aggregates
NZ571610A NZ571610A (en) 2006-04-04 2007-04-04 A process for concentration of alpha mannosidase
NZ597548A NZ597548A (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide
NZ568728A NZ568728A (en) 2006-04-04 2007-04-04 A process for concentration of a aryl sulfatase A

Family Applications After (6)

Application Number Title Priority Date Filing Date
NZ607595A NZ607595A (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide
NZ588903A NZ588903A (en) 2006-04-04 2007-04-04 A process for concentration of galactosycerebrosidase or porphobuilinogen deaminase
NZ582045A NZ582045A (en) 2006-04-04 2007-04-04 A pharmaceutical composition comprising at least 10mg/mL of alfa mannosidase and less that 5% total protein aggregates
NZ571610A NZ571610A (en) 2006-04-04 2007-04-04 A process for concentration of alpha mannosidase
NZ597548A NZ597548A (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide
NZ568728A NZ568728A (en) 2006-04-04 2007-04-04 A process for concentration of a aryl sulfatase A

Country Status (20)

Country Link
US (6) US20090246187A1 (https=)
EP (4) EP2004672B1 (https=)
JP (6) JP2009532394A (https=)
KR (3) KR20140057678A (https=)
CN (1) CN105233276A (https=)
AU (2) AU2007234195B2 (https=)
BR (1) BRPI0709737A2 (https=)
CA (3) CA2644642C (https=)
DK (1) DK2628746T3 (https=)
ES (3) ES2928096T3 (https=)
HU (1) HUE042402T2 (https=)
IL (4) IL194267A (https=)
MX (1) MX2008012748A (https=)
NO (3) NO347673B1 (https=)
NZ (7) NZ623123A (https=)
PL (3) PL2631242T3 (https=)
PT (1) PT2628746T (https=)
SI (1) SI2628746T1 (https=)
WO (1) WO2007112757A2 (https=)
ZA (2) ZA200805346B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8536315B2 (en) 2004-01-30 2013-09-17 Shire Pharmaceuticals Ireland Limited Production and purification of recombinant arylsulftase
ES2928096T3 (es) * 2006-04-04 2022-11-15 Takeda Pharmaceuticals Co Un proceso para la concentración de un polipéptido
DK2538968T3 (en) * 2010-02-24 2017-12-11 Chiesi Farm Spa PROCEDURE FOR THE PREPARATION AND PURIFICATION OF RECOMBINANT LYSOSOMAL ALFA MANNOSIDASE
RS62620B1 (sr) 2010-06-25 2021-12-31 Shire Human Genetic Therapies Metode i kompozicije za isporuku cns akrilsulfataze a
SMT201600385T1 (it) 2010-06-25 2017-03-08 Shire Human Genetic Therapies Trasporto di agenti terapeutici all’snc
NZ605873A (en) * 2010-06-25 2015-02-27 Shire Human Genetic Therapies Methods and compositions for cns delivery of arylsulfatase a
NZ605874A (en) 2010-06-25 2015-02-27 Shire Human Genetic Therapies Methods and compositions for cns delivery of heparan n-sulfatase
ES2625511T3 (es) 2011-07-08 2017-07-19 Shire Human Genetic Therapies, Inc. Métodos para la purificación de arylsulfatasa A
US20140377244A1 (en) 2011-12-23 2014-12-25 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
CN104854122B (zh) * 2012-11-13 2021-10-08 意大利凯西制药公司 重组人半乳糖脑苷脂-β-半乳糖苷酶(rhGALC)的纯化
AU2013357812B2 (en) * 2012-12-11 2019-10-10 Centogene Gmbh Method for the diagnosis of metachromatic leukodystrophy
AU2014205441B2 (en) 2013-01-09 2019-12-12 Takeda Pharmaceutical Company Limited Methods for purification of arylsulfatase A
AR095527A1 (es) 2013-03-15 2015-10-21 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix
EA202092926A3 (ru) 2014-03-24 2021-10-29 Биовератив Терапьютикс Инк. Лиофилизированные составы, содержащие фактор ix
US11584777B2 (en) 2017-08-31 2023-02-21 Green Cross Corporation Method for purifying a sulfatase protein
KR102290596B1 (ko) 2020-09-10 2021-08-19 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 주사용 조성물 및 이의 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2041280A1 (en) 1990-05-10 1991-11-11 Yosuke Sawada Arylsulfatase
NO960163D0 (no) 1996-01-15 1996-01-15 Thomas Berg Mutasjonsdeteksjon av bovin
AU750143B2 (en) 1998-01-27 2002-07-11 Zymenex A/S Method for treating acute intermittent porphyria (AIP) and other porphyric diseases
NZ509135A (en) * 1998-06-09 2002-10-25 Statens Seruminstitut A third generation intravenous immunoglobulin G (IVIG) purified using column chromatographic ion exchange methods
DK2270044T3 (en) * 1998-06-09 2015-01-26 Csl Behring Ag Liquid immunoglobulin G (IgG) product
US6537777B1 (en) 1998-07-27 2003-03-25 Hemebiotech A/S Human porphobilinogen deaminase sequences
AUPQ026799A0 (en) * 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
WO2001007065A2 (en) * 1999-07-27 2001-02-01 Hemebiotech A/S PRODUCTION OF rhPBGD AND NEW THERAPEUTIC METHODS FOR TREATING PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP) AND OTHER PORPHYRIC DISEASES
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
CA2429210A1 (en) 2000-11-15 2002-05-23 Jason C. Goodrick Expression system for recombinant proteins
AU2002317700A1 (en) * 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
AU2002317701A1 (en) * 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human lysosomal alpha-mannosidase
EP1402014A1 (en) 2001-06-29 2004-03-31 Hemebiotech A/S A process for purification of recombinant porphobilinogen deaminase
US7232670B2 (en) * 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
AU2003222568B2 (en) 2002-01-11 2009-05-07 Bioasis Technologies, Inc. Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
WO2003066669A2 (en) * 2002-02-04 2003-08-14 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
CH694697A5 (de) 2004-01-29 2005-06-15 Koelbl Engineering Und Consult Gummimehl-enthaltende Elastomerlegierungen.
US8536315B2 (en) * 2004-01-30 2013-09-17 Shire Pharmaceuticals Ireland Limited Production and purification of recombinant arylsulftase
SI1740204T1 (en) 2004-04-01 2018-07-31 Chiesi Farmaceutici S.P.A. MEDICAL APPLICATION OF ALFA-MANOSIDES
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
ES2928096T3 (es) * 2006-04-04 2022-11-15 Takeda Pharmaceuticals Co Un proceso para la concentración de un polipéptido

Also Published As

Publication number Publication date
CA2632528A1 (en) 2007-10-11
EP2628746A3 (en) 2014-03-19
HUE042402T2 (hu) 2019-06-28
NZ571610A (en) 2011-07-29
WO2007112757A3 (en) 2008-02-28
PT2628746T (pt) 2019-04-23
NZ588903A (en) 2012-08-31
IL211905A0 (en) 2011-05-31
ES2744499T3 (es) 2020-02-25
EP2631242A3 (en) 2013-10-02
NO20084776L (no) 2008-10-31
PL2100898T3 (pl) 2019-11-29
KR101504969B1 (ko) 2015-03-24
AU2007234195A1 (en) 2007-10-11
IL194267A0 (en) 2011-08-01
CA2882501C (en) 2021-09-07
DK2628746T3 (en) 2019-04-01
CN105233276A (zh) 2016-01-13
JP2013236633A (ja) 2013-11-28
EP2628746B1 (en) 2019-01-09
JP2014051503A (ja) 2014-03-20
NZ582045A (en) 2011-07-29
MX2008012748A (es) 2009-01-07
US8809055B2 (en) 2014-08-19
US20090246187A1 (en) 2009-10-01
US20140314735A1 (en) 2014-10-23
EP2631242B1 (en) 2022-08-03
PL2631242T3 (pl) 2023-03-20
NO20082510L (no) 2008-10-31
EP2100898B1 (en) 2019-06-19
AU2007234195B2 (en) 2013-02-07
CA2644642A1 (en) 2007-10-11
BRPI0709737A2 (pt) 2011-07-26
EP2628746A2 (en) 2013-08-21
NZ568728A (en) 2011-09-30
NZ607595A (en) 2014-10-31
JP2009532394A (ja) 2009-09-10
US20160193304A1 (en) 2016-07-07
NO20211305A1 (no) 2008-10-31
AU2008229659B2 (en) 2013-01-31
NZ597548A (en) 2013-08-30
PL2628746T3 (pl) 2019-07-31
CA2644642C (en) 2016-01-26
JP2014058521A (ja) 2014-04-03
IL241654B (en) 2019-02-28
IL194267A (en) 2015-10-29
NO346368B1 (no) 2022-06-27
KR20150103339A (ko) 2015-09-09
NO347673B1 (no) 2024-02-19
JP5878152B2 (ja) 2016-03-08
ES2928096T3 (es) 2022-11-15
JP2016104000A (ja) 2016-06-09
SI2628746T1 (sl) 2019-04-30
JP5384232B2 (ja) 2014-01-08
US20170202927A1 (en) 2017-07-20
IL241654A0 (en) 2015-11-30
EP2004672A2 (en) 2008-12-24
EP2004672B1 (en) 2015-08-19
US20180289777A1 (en) 2018-10-11
KR20140057678A (ko) 2014-05-13
KR20090018894A (ko) 2009-02-24
US9713634B2 (en) 2017-07-25
AU2008229659A1 (en) 2008-10-23
EP2100898A1 (en) 2009-09-16
EP2631242A2 (en) 2013-08-28
CA2882501A1 (en) 2007-10-11
IL235982A0 (en) 2015-01-29
WO2007112757A2 (en) 2007-10-11
ZA200805346B (en) 2018-11-28
US20120076767A1 (en) 2012-03-29
JP2009273469A (ja) 2009-11-26
ZA200809540B (en) 2019-09-25
CA2632528C (en) 2022-07-12
ES2713488T3 (es) 2019-05-22

Similar Documents

Publication Publication Date Title
NZ623123A (en) A process for concentration of a polypeptide
ES2650689T3 (es) Administración de agentes terapéuticos al sistema nervioso central
EP2175834B8 (en) Glp-1-fc fusion protein formulation
NZ702803A (en) Cns delivery of therapeutic agents
MX2007004882A (es) Derivados de xantina con actividad de receptor de hm74a.
BRPI0412909A (pt) uso de rnai inibindo atividade de parp para a fabricação de um medicamento para o tratamento de cáncer
WO2005023083A3 (en) Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
NZ595526A (en) Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant
NZ595193A (en) Modified Proteases That Inhibit Complement Activation
IL209951A (en) Use of n-butyl-dioxinogirimycin and enzyme replacement therapy to make a drug for the treatment of pomp
WO2007091250A3 (en) Enzyme replacement therapy for treating lysosomal storage diseases
HRP20130406T1 (hr) Medikamenti s aktivnošä†u prema receptoru hm74a
UA92348C2 (en) 17b-HSD1 AND STS INHIBITORS
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
BRPI0510817A (pt) protease, uso de uma protease, composição farmacêutica, e, método para o tratamento de uma doença
IL165858A0 (en) Pharmaceutical preparation and method for treatment of human malignancies with arginine deprivation
NZ601592A (en) Recombinant elastase proteins and methods of manufacturing and use thereof
GB2446341A (en) Method and system for transdermal drug delivery
WO2006100679A3 (en) Recombinant antibodies against human type ii transglutaminase and uses thereof
MX2008001520A (es) Composiciones de tizanidina y metodos de tratamiento usando las composiciones.
WO2007056301A3 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
WO2008060535A3 (en) Use of reversine and analogs for treatment of cancer
GB0623258D0 (en) Thiadiazole derivatives for the treatment of neuro-degenerative diseases
WO2006138571A3 (en) Composition and methods for treating complications associated with ingestion of a medicinal, chemical or biological substance
WO2005056520A8 (en) Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 04 APR 2017 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20151118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2018 BY DENNEMEYER + CO.

Effective date: 20170331

ASS Change of ownership

Owner name: CHIESI FARMACEUTICI S.P.A., IT

Effective date: 20170608

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2019 BY COMPUTER PACKAGES INC

Effective date: 20180331

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2020 BY COMPUTER PACKAGES INC

Effective date: 20190319

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2021 BY COMPUTER PACKAGES INC

Effective date: 20200318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2022 BY COMPUTER PACKAGES INC

Effective date: 20210330

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2023 BY COMPUTER PACKAGES INC

Effective date: 20220317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2024 BY COMPUTER PACKAGES INC

Effective date: 20230317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2025 BY COMPUTER PACKAGES INC

Effective date: 20240330

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2026 BY COMPUTER PACKAGES INC

Effective date: 20250317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2027 BY COMPUTER PACKAGES INC

Effective date: 20260317